Center-Authored Papers

Filters: Author is Tykodi, Scott S  [Clear All Filters]
B
Bhatia S, Tykodi SS, Lee SM, Thompson JA.  2015.  Systemic therapy of metastatic melanoma: on the road to cure.. Oncology (Williston Park, N.Y.). 29(2):126-35. Abstract
Bhatia S, Tykodi SS, Thompson JA.  2009.  Treatment of metastatic melanoma: an overview.. Oncology (Williston Park, N.Y.). 23(6):488-96. Abstract
Brahmer JR, Tykodi SS, Chow LQM, Hwu W-J, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K et al..  2012.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer.. The New England journal of medicine. 366(26):2455-65. Abstract
E
Escudier B, Sharma P, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER et al..  2017.  CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.. European urology. Abstract
F
Foxx-Lupo WT, Sing S, Alwan L, Tykodi SS.  2015.  A Drug Interaction Between Cabozantinib and Warfarin in a Patient With Renal Cell Carcinoma.. Clinical genitourinary cancer.
G
George S, Motzer RJ, Hammers HJ, Redman BG, Kuzel TM, Tykodi SS, Plimack ER, Jiang J, Waxman IM, Rini BI.  2016.  Safety and Efficacy of Nivolumab in Patients With Metastatic Renal Cell Carcinoma Treated Beyond Progression: A Subgroup Analysis of a Randomized Clinical Trial.. JAMA oncology. 2(9):1179-1186. Abstract
Goodridge JP, Lee N, Burian A, Pyo C-W, Tykodi SS, Warren EH, Yee C, Riddell SR, Geraghty DE.  2013.  HLA-F and MHC-I Open Conformers Cooperate in a MHC-I Antigen Cross-Presentation Pathway.. Journal of immunology (Baltimore, Md. : 1950). 191(4):1567-77. Abstract
M
Macleod LC, Tykodi SS, Holt SK, Wright JL, Lin DW, Tretiakova MS, True LD, Gore JL.  2015.  Trends in Metastatic Kidney Cancer Survival From the Cytokine to the Targeted Therapy Era.. Urology. Abstract
Motzer RJ, Escudier B, McDermott DF, George S, Hammers HJ, Srinivas S, Tykodi SS, Sosman JA, Procopio G, Plimack ER et al..  2015.  Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma.. The New England journal of medicine. 373(19):1803-1813. Abstract
T
Torikai H, Reik A, Soldner F, Warren EH, Yuen C, Zhou Y, Crossland DL, Huls H, Littman N, Zhang Z et al..  2013.  Towards eliminating HLA class I expression to generate universal cells from allogeneic donors.. Blood. 122(8):1341-9. Abstract
Tykodi SS, Thompson JA.  2008.  Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer.. Expert opinion on biological therapy. 8(12):1947-53. Abstract
Tykodi SS, Sandmaier BM, Warren EH, Thompson JA.  2011.  Allogeneic hematopoietic cell transplantation for renal cell carcinoma: ten years after.. Expert opinion on biological therapy. 11(6):763-73. Abstract
Tykodi SS, Fujii N, Vigneron N, Lu SM, Mito JK, Miranda MX, Chou J, Voong LN, Thompson JA, Sandmaier BM et al..  2008.  C19orf48 encodes a minor histocompatibility antigen recognized by CD8+ cytotoxic T cells from renal cell carcinoma patients.. Clinical cancer research : an official journal of the American Association for Cancer Research. 14(16):5260-9. Abstract
Tykodi SS.  2013.  Progress and potential of immune checkpoint blockade for treating advanced renal cell carcinoma.. Immunotherapy. 5(6):607-19. Abstract
Tykodi SS, Satoh S, Deming JD, Chou J, Harrop R, Warren EH.  2012.  CD8+ T-cell clones specific for the 5T4 antigen target renal cell carcinoma tumor-initiating cells in a murine xenograft model.. Journal of immunotherapy (Hagerstown, Md. : 1997). 35(7):523-33. Abstract
W
Wrangle J, Wang W, Koch A, Easwaran H, Mohammad HP, Vendetti F, Vancriekinge W, Demeyer T, Du Z, Parsana P et al..  2013.  Alterations of immune response of non-small cell lung cancer with Azacytidine.. Oncotarget. 4(11):2067-79. Abstract